PSMA PET/CT Guidance Linked to Longer Biochemical Control in Oligometastatic Castration
A study of 102 patients suggests that using PSMA PET/CT imaging to guide metastasis-directed therapy may improve survival outcomes in castration-resistant prostate cancer. Researchers noted that while promising, the retrospective nature of the study prevents establishing a direct causal link.
Why it matters
Advancements in precision imaging could significantly improve treatment planning and life expectancy for patients with advanced prostate cancer.
An updated analysis of the PRECISE-MDT cohort has found that metastasis-directed therapy guided by prostate-specific membrane antigen PET/CT was associated with longer biochemical recurrence–free survival and improved overall survival in patients with oligometastatic castration-resistant prostate cancer.
The report summarizes medical research findings objectively, including necessary caveats about study limitations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in